Peritoneal Dialysis Update

Aug 27, 2026

Episode · 14 min

Highlights

  1. 01Core Interventions for the Prevention of Peritoneal Dialysis-Related Infections.

    Clinical Journal of the American Society of Nephrology

    PMID 41348491

  2. 02The effect of icodextrin on peritoneal dialysis patients with congestive heart failure: a time-varying exposure design and target trial emulation approach.

    Nephrology Dialysis Transplantation

    PMID 41388906

  3. 03Toward a Peritoneal Dialysis-First Policy in the United Kingdom and Europe: A Phenotype-Based Analysis of Survival and System-Level Implications.

    Clinical Journal of the American Society of Nephrology

    PMID 42018371

  4. 04Peritoneal Dialysis Initiation Patterns by Health Service Area during an Era of Expansion.

    Journal of the American Society of Nephrology

    PMID 41563792

  5. 05Hospitalization Risk in the Integrated Home Dialysis Model: Analysis of the Canadian Organ Replacement Register.

    Clinical Journal of the American Society of Nephrology

    PMID 42008299

  6. 06Topical Timolol for Peritoneal Dialysis Catheter Exit-Site Granulomas: First Report of Successful Use in CAPD Patients.

    Seminars in Dialysis

    PMID 42472895

Read the briefing

Welcome to your bi-weekly update in Peritoneal Dialysis. This briefing covers 6 papers from the past 14 days.

The first paper addresses a major clinical challenge in peritoneal dialysis: standardizing infection prevention to reduce peritonitis and exit-site infections. Peritonitis remains a primary driver of technique failure, hospitalization, and mortality in this patient population, yet prevention practices vary widely across clinical sites. To address these inconsistencies, Perl and colleagues published a consensus-based framework outlining core interventions developed under the auspices of the American Society of Nephrology. The authors utilized an iterative expert review process to synthesize current evidence and international guidelines into a set of highly actionable strategies for clinical teams. The framework highlights six core interventions. First, clinics should establish regular surveillance and feedback on infection rates to identify local trends. Second, they must implement standardized staff training and competency assessments to ensure clinical teams maintain high standards. Third, standardized education must extend to patients and their care partners, ensuring they are fully equipped for home care. Fourth, clinical teams should conduct routine, structured infection prevention assessments. Fifth, the guidelines recommend routine antimicrobial prophylaxis for peritoneal dialysis catheter exit sites. Finally, clinics should administer prophylactic antimicrobials for specific procedures and events, such as dental work or invasive interventions. While these consensus recommendations are grounded in established clinical trial data, the authors acknowledge that their success depends heavily on consistent, facility-level implementation and ongoing quality improvement efforts. For practicing clinicians, this paper provides a valuable checklist to audit and refine local protocols, ultimately aiming to lower infection rates and support the successful expansion of home-based dialysis.

Moving to our second paper, we look at fluid management in peritoneal dialysis patients who also suffer from congestive heart failure. Managing volume status in these high-risk individuals is exceptionally difficult, and while icodextrin is known for its favorable ultrafiltration and metabolic properties, robust evidence regarding its impact on survival in this specific cohort has been limited. Ma and colleagues addressed this gap by conducting a retrospective cohort study using a target trial emulation framework to examine the association between icodextrin use and clinical outcomes. Analyzing data from eighteen hundred patients in Taiwan with pre-existing congestive heart failure, the researchers compared individuals who used icodextrin for at least half of their dialysis duration with those who did not. To account for the dynamic nature of prescription patterns, the investigators utilized multivariable models incorporating time-varying exposure. The findings were striking. The use of icodextrin was associated with a dramatic reduction in mortality and cardiovascular events. Specifically, icodextrin use cut the risk of all-cause mortality by more than eighty percent, reduced cardiovascular mortality by four-fifths, and lowered the risk of sudden death by eighty-five percent. Additionally, the risk of major adverse cardiovascular events was reduced by about a third. Patients using icodextrin also experienced a lower rate of transition to hemodialysis and a reduced risk of encapsulating peritoneal sclerosis. Although the study is limited by its retrospective design and potential for residual confounding, the rigorous target trial emulation approach strengthens the validity of these findings. For clinicians, these results suggest that icodextrin should be the preferred osmotic agent for peritoneal dialysis patients with congestive heart failure, offering a powerful tool to improve both cardiovascular health and overall survival in this vulnerable population.

Shifting gears to our third paper, we examine a massive cohort study that supports the clinical and policy push toward a peritoneal dialysis-first approach. Whether peritoneal dialysis offers a survival advantage over hemodialysis in contemporary practice has remained a subject of ongoing debate, particularly when accounting for the diverse characteristics of patients and the competing risk of kidney transplantation. To clarify this, Ali and colleagues analyzed data from the United Kingdom Renal Registry, evaluating over ninety-six thousand adults who initiated dialysis between 2007 and 2021. The researchers used unsupervised clustering to categorize patients into three distinct clinical phenotypes based on age, sex, ethnicity, kidney disease etiology, hemoglobin, albumin, and transplant-listing status. They then modeled the cumulative incidence of death before transplantation, treating transplant as a competing event. Across the entire cohort, about a quarter of patients initiated peritoneal dialysis, while about three quarters of patients initiated hemodialysis. The analysis revealed that hemodialysis was associated with higher mortality during the active dialysis phase across all three patient phenotypes. At one year, the risk of death was significantly higher for those on hemodialysis. While this association persisted at five years, the magnitude of the risk difference attenuated with increasing age. Specifically, in the youngest phenotype, patients on hemodialysis had more than double the mortality risk of their peers on peritoneal dialysis, whereas in the oldest, most frail phenotype, the survival difference was much smaller, showing only a modest increase in mortality for the hemodialysis group. Although registry-based studies carry inherent limitations, such as the potential for unmeasured confounding, the sheer size and robust phenotyping of this study provide strong support for a peritoneal dialysis-first strategy. Clinicians can use these phenotype-specific insights to guide shared decision-making, offering reassurance that peritoneal dialysis is a safe and often superior initial modality across a broad spectrum of patients.

Our fourth paper shifts the focus to health policy and equity, examining how the expansion of peritoneal dialysis has played out geographically across the United States. In the past, the use of peritoneal dialysis was highly concentrated in specific, often wealthier, regions, raising concerns that national efforts to expand home dialysis might only benefit areas that already had established programs. Knapp and colleagues addressed this question by analyzing data from the United States Renal Data System, tracking more than one million incident dialysis patients across more than seven hundred health service areas between 2011 and 2020. The researchers categorized geographic areas based on their baseline use of peritoneal dialysis in 2009 and 2020, dividing them into low, medium, and high-use categories. They then evaluated how the odds of a patient initiating peritoneal dialysis changed over a ten-year period of national expansion. The results demonstrate a true broadening of access. The odds of initiating peritoneal dialysis increased most rapidly in communities that historically had the lowest use, rising by about half over every five-year period. In contrast, areas with historically high use saw a much more modest increase of under twenty percent. Impressively, just over half of the geographic areas that started the decade in the low-use category had successfully transitioned to medium or high-use categories by 2020. While this registry-based analysis cannot pinpoint the exact clinical or economic drivers behind these regional shifts, it clearly demonstrates that the growth of home dialysis in the United States has been equitable and widespread, rather than confined to existing centers of excellence. For clinical leaders and policy makers, these findings are highly encouraging, proving that targeted efforts can successfully overcome geographic barriers and establish viable home dialysis pathways in historically underserved communities.

The fifth paper explores the clinical realities of the integrated home dialysis model, specifically looking at what happens when a patient transitions from peritoneal dialysis to home hemodialysis. While this integrated approach is theoretically appealing, allowing patients to maximize their time on home-based therapies, the actual risks associated with the transition process itself have not been well characterized. Desbiens and colleagues used the Canadian Organ Replacement Register to analyze a propensity score-matched cohort of patients initiating home dialysis between 2005 and 2018. They compared about three hundred patients who transitioned from peritoneal dialysis to home hemodialysis with about seven hundred patients who initiated home hemodialysis directly. The researchers defined a transition window spanning the final month of peritoneal dialysis, any interim period on facility hemodialysis, and the first month of home hemodialysis. The study revealed a significant spike in hospitalizations during this transition period, with rates reaching more than two hospitalizations per patient-year. Transitioning patients faced nearly triple the risk of hospitalization during this window compared to those who started home hemodialysis directly, and infectious complications accounted for nearly a third of these hospitalizations. Interestingly, the risk of hospitalization was also elevated in the year leading up to the transition, but once the transition was complete, the hospitalization rate normalized and matched that of the direct-start group. Furthermore, this temporary spike in risk was far less pronounced among patients who experienced shorter transitions, defined as spending fewer than ninety days on interim facility hemodialysis. This study highlights a critical period of vulnerability for patients undergoing modality transitions. Clinicians should anticipate this heightened risk, implement close monitoring for infectious complications, and actively work to minimize the duration of interim facility hemodialysis to ensure a safer transition.

Our final paper is a highly practical case report that introduces a novel, non-invasive solution for a common and troublesome clinical issue: catheter exit-site granulomas. These benign vascular lesions are a frequent complication for patients on peritoneal dialysis, and because they bleed easily and harbor bacteria, they significantly increase the risk of exit-site infections and subsequent peritonitis. Standard treatments, such as silver nitrate cauterization or surgical excision, can be painful and carry their own risks of tissue damage or infection. S VM and colleagues described a novel approach using topical point-five percent timolol maleate ophthalmic solution, a beta-blocker commonly used for glaucoma, which has recently shown promise in promoting the regression of infantile hemangiomas and other vascular lesions. The authors applied this solution locally to the exit-site granulomas of two patients undergoing continuous ambulatory peritoneal dialysis. The timolol drops were applied three times weekly as part of routine exit-site care, and clinical progress was monitored photographically. In both cases, the granulomas resolved completely, with one patient achieving full resolution within three weeks and the other within two months. Neither patient experienced local or systemic adverse effects, and no exit-site infections occurred during the treatment period. While this report is limited by its extremely small sample size of only two patients, the mechanism of beta-blocker-induced vasoconstriction and inhibition of angiogenesis offers a highly plausible explanation for the rapid regression of the granulomatous tissue. This simple, inexpensive, and painless intervention represents a promising alternative to invasive therapies, and clinicians might consider discussing this off-label option with patients suffering from persistent exit-site granulomas while we await larger validating studies.

When we look across these six papers, a clear theme emerges regarding the maturation and refinement of peritoneal dialysis as a primary home modality. We are seeing a shift from simply expanding access to optimizing the entire lifecycle of the peritoneal dialysis patient. This trend is evident in the push for standardized infection prevention guidelines from the American Society of Nephrology, and the geographical data showing that peritoneal dialysis is now reaching communities that historically lacked home-care infrastructure. Furthermore, as our patient population grows, we are learning how to better manage high-risk subgroups, such as using icodextrin to improve survival in those with congestive heart failure, and carefully managing the high-risk transition window when patients move to home hemodialysis. Even small, practical innovations, like using topical timolol for exit-site granulomas, play a vital role in preserving the peritoneal membrane and maintaining catheter patency over the long term. Together, these studies provide a roadmap for clinicians to deliver safer, more equitable, and highly individualized care.

That's your Peritoneal Dialysis update for this period. Until next time, stay evidence-based.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.

Get this every week in your podcast app.

New research episodes land in your feed automatically. Listen on your commute.

Spot something worth flagging?